Latest News
Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals Announces Interim Data from Tau Clinical Trial, FDA Consultation for FTD-MAPT and PSP Studies - AFTD
- Arrowhead Pharmaceuticals reports strong ARO-MA...
- Arrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data drop
- Arrowhead’s brain shuttle milestone meets tau’s dose dilemma
- Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study
- Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
- Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit
- Arrowhead’s brain-targeting drug lowers Alzheimer’s tau protein in early study
- Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial
- Why is Arrowhead Pharmaceuticals stock surging today?
- Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher
- Is Arrowhead Pharmaceuticals (ARWR) Stock Still Reasonable After Trial Results?
Headlines from the last 30 days, linking to the original publishers. See all market news →